Learn More-External Link
Trending at Lumira Ventures
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Learn More-External Link
Ron Ho Named President & CEO of U-Systems, Inc.
Learn More-External Link
Pharmasset Announces Consummation of $24.18 Million…
Learn More-External Link
Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
Learn More-External Link
Archemix’ ARC1779 Granted Orphan Designation in EU…
CAMBRIDGE, Mass. — Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that ARC1779 has received orphan drug designation from the European Commission (EC). ARC1779 also received orphan drug designation …
The Guava Nexin Assay
Learn More-External Link
Pharmasset Joins Russell 3000 Index
Learn More-External Link
Pharmasset Receives Notice of Allowance
Learn More-External Link
“Bill of Health” -Robo Replacements
Learn More-External Link
Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data…
Learn More-External Link
Simple Reproducible Assay for Detection of Early and Late Apoptosis
Learn More-External Link
TransMolecular Reports Positive Pharmacokinetic Data From Tumor Drug Study
Learn More-External Link
Pharmasset Inc files for $100 mln debt, stock offer
Learn More-External Link